NeOnc Technologies Receives Written Feedback From FDA Regarding CMC Development Program For NEO212, Temozolomide-Perillyl Alcohol Conjugate; Co. Cancels July Meeting

뉴스 본문을 불러오고 있어요.

NeOnc Technologies Receives Written Feedback From FDA Regarding CMC Development Program For NEO212, Temozolomide-Perillyl Alcohol Conjugate; Co. Cancels July Meeting | 웨이프 WAPE

NeOnc Technologies Receives Written Feedback From FDA Regarding CMC Development Program For NEO212, Temozolomide-Perillyl Alcohol Conjugate; Co. Cancels July Meeting

기사 요약

관련 종목

댓글 —